BioAtla Operating Income 2020-2021 | BCAB

BioAtla operating income from 2020 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
BioAtla Annual Operating Income
(Millions of US $)
2020 $-30
2019 $-28
BioAtla Quarterly Operating Income
(Millions of US $)
2021-06-30 $-30
2021-03-31 $-19
2020-06-30 $-5
2020-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.056B $0.000B
BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71